Q-omics provides the consensus-scored KLRG1 profile across patient tissues and cancer cell-line models. KLRG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KLRG1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, KLRG1 RNA expression shows 18,022 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KICH, and UVM as cancer lineages where KLRG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLRG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLRG1 survival associations across molecular data types. KLRG1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLRG1 RNA expression–survival associations across cancer types. High KLRG1 expression shows unfavorable associations in LAML, KIRP and UVM, but favorable associations in LUAD, HNSC and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KLRG1 RNA expression.
This table summarizes KLRG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLRG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLRG1 shows lower tumor expression in KICH, THCA, LUSC, LUAD and COAD and higher tumor expression in KIRC. The KICH box plot shows higher KLRG1 RNA expression in normal versus tumor tissue (log2 FC = −1.401, t-test p < 0.001).
This table shows molecular features associated with KLRG1 in patient tissues and cancer cell lines. In patient samples, KLRG1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLRG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
